Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...
Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH),which is expected to begin in 2H 2025Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback